Level Four Advisory Services’s Castle Biosciences CSTL Stock Holding History

Level Four Advisory Services’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,265	Closed	-$350K	–	653
2021 Q3	$350K	Buy	+5,265	New	+$370K	0.04%	356

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Level Four Advisory Services's CSTL Position: Q4 2021 in Review

Level Four Advisory Services sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 5,265 shares — an estimated $350K sold.

Level Four Advisory Services first reported a position in CSTL in Q3 2021 and held it in 1 quarter. The position peaked at $350K in Q3 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

Level Four Advisory Services reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
Level Four Advisory Services sold 5,265 Castle Biosciences shares in Q4 2021, an estimated $350K.
Level Four Advisory Services first reported a position in Castle Biosciences in Q3 2021 and held it in 1 quarter.
Level Four Advisory Services's Castle Biosciences position peaked at $350K in Q3 2021.
159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Level Four Advisory Services's 13F filing for Q4 2021, filed 11 Feb 2022.